# Adrenarche as a regulator of sensitivity to early adversity

**Authors:** J. Herbert

PMC · DOI: 10.1111/jne.70149 · Journal of Neuroendocrinology · 2026-02-24

## TL;DR

The paper explores how adrenarche, a hormonal transition in early childhood, moderates the brain's sensitivity to early adversity and affects long-term mental health.

## Contribution

The study proposes a novel role for adrenarche in regulating the brain's response to early adversity through cortisol and DHEA(S) interactions.

## Key findings

- Adrenarche moderates cortisol's effects on brain plasticity and memory formation.
- DHEA(S) opposes cortisol's actions, stabilizing psychological traits formed before adrenarche.
- The transition at adrenarche alters neural mechanisms like perineuronal nets and serotonin activity.

## Abstract

The human brain is highly sensitive to early adversity, which can have long‐term consequences for later mental health. It is also a time of rapid learning of social, motor and other skills, including language. It is proposed that pre‐adrenarche, the only epoch in human development in which cortisol is not accompanied by dehydroepiandrosterone (DHEA) and its sulphated derivative (DHEAS), represents the sensitive period but this is subsequently moderated by the advent of adrenarche and the surge of DHEA(S) at 6–8 years. Cortisol enhances plasticity and the formation of new memories as well as personality traits such as emotionality. DHEA(S) is well known to oppose many of the actions of cortisol on the brain, including those on learning, memory and synaptic function, all reflecting altered plasticity; adrenarche is therefore a time of moderated cortisol activity. Several endocrine‐dependent neural mechanisms respond to the neuroendocrine transition at adrenarche, including alterations in perineuronal nets, gene expression of growth factors, serotonin activity, cytokine release and synaptic adaptability. Adrenarche will reduce the detrimental impact of adverse events but stabilise memories and psychological traits acquired during the cortisol‐dominated pre‐adrenarche epoch. The transition from pre‐ to post‐adrenarche is therefore a highly significant neuroendocrine event in early life, with both potentially beneficial and disadvantageous consequences. This suggests a primary role for adrenarche, for which no function has yet been established.

## Linked entities

- **Chemicals:** cortisol (PubChem CID 5754), dehydroepiandrosterone (PubChem CID 5881), DHEA (PubChem CID 5881), DHEAS (PubChem CID 12594)

## Full-text entities

- **Genes:** NTRK2 (neurotrophic receptor tyrosine kinase 2) [NCBI Gene 4915] {aka DEE58, EIEE58, GP145-TrkB, OBHD, TRKB, trk-B}, BDNF (brain derived neurotrophic factor) [NCBI Gene 627] {aka ANON2, BULN2}, COMT (catechol-O-methyltransferase) [NCBI Gene 1312] {aka HEL-S-98n}, H6PD (hexose-6-phosphate dehydrogenase/glucose 1-dehydrogenase) [NCBI Gene 9563] {aka CORTRD1, G6PDH, GDH, H6PDH}, Bdnf (brain derived neurotrophic factor) [NCBI Gene 12064], Cx3cr1 (C-X3-C motif chemokine receptor 1) [NCBI Gene 13051] {aka mCX3CR1}, Mmp9 (matrix metallopeptidase 9) [NCBI Gene 17395] {aka B/MMP9, Clg4b, Gel B, MMP-9, pro-MMP-9}, Otx2 (orthodenticle homeobox 2) [NCBI Gene 18424] {aka E130306E05Rik}, CYP17A1 (cytochrome P450 family 17 subfamily A member 1) [NCBI Gene 1586] {aka CPT7, CYP17, P450C17, S17AH}, HSD11B1 (hydroxysteroid 11-beta dehydrogenase 1) [NCBI Gene 3290] {aka 11-DH, 11-beta-HSD1, CORTRD2, HDL, HSD11, HSD11B}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, PVALB (parvalbumin) [NCBI Gene 5816] {aka D22S749}, GALNS (galactosamine (N-acetyl)-6-sulfatase) [NCBI Gene 2588] {aka GALNAC6S, GAS, GalN6S, MPS4A}, NGF (nerve growth factor) [NCBI Gene 4803] {aka Beta-NGF, HSAN5, NGFB}, HTR1A (5-hydroxytryptamine receptor 1A) [NCBI Gene 3350] {aka 5-HT-1A, 5-HT1A, 5HT1a, ADRB2RL1, ADRBRL1, G-21}, IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}, Gad2 (glutamic acid decarboxylase 2) [NCBI Gene 14417] {aka 6330404F12Rik, GAD(65), GAD65, Gad-2}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, Pnn (pinin) [NCBI Gene 18949] {aka D12Ertd512e}, SLC6A4 (solute carrier family 6 member 4) [NCBI Gene 6532] {aka 5-HTT, 5-HTTLPR, 5HTT, HTT, OCD1, SERT}, CRHR2 (corticotropin releasing hormone receptor 2) [NCBI Gene 1395] {aka CRF-RB, CRF2, CRFR2, HM-CRF}, Sema3a (sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3A) [NCBI Gene 20346] {aka Hsema-I, SEMA1, SemD, Semad, coll-1}, FKBP5 (FKBP prolyl isomerase 5) [NCBI Gene 2289] {aka AIG6, FKBP51, FKBP54, P54, PPIase, Ptg-10}, IL27RA (interleukin 27 receptor subunit alpha) [NCBI Gene 9466] {aka CRL1, IL-27RA, IL27R, TCCR, WSX1, zcytor1}, POMC (proopiomelanocortin) [NCBI Gene 5443] {aka ACTH, CLIP, LPH, MSH, NPP, OBAIRH}, CRHR1 (corticotropin releasing hormone receptor 1) [NCBI Gene 1394] {aka CRF-R, CRF-R-1, CRF-R1, CRF1, CRFR-1, CRFR1}, G6PD (glucose-6-phosphate dehydrogenase) [NCBI Gene 2539] {aka CNSHA1, G6PD1}, Has3 (hyaluronan synthase 3) [NCBI Gene 15118], HTR2C (5-hydroxytryptamine receptor 2C) [NCBI Gene 3358] {aka 5-HT1C, 5-HT2C, 5-HTR2C, 5HTR2C, HTR1C}, NTRK1 (neurotrophic receptor tyrosine kinase 1) [NCBI Gene 4914] {aka MTC, TRK, TRK1, TRKA, Trk-A, p140-TrkA}, Pvalb (parvalbumin) [NCBI Gene 19293] {aka PV, Parv, Pva}
- **Diseases:** neglect (MESH:D058069), drug misuse (MESH:D009293), ROLE OF SEROTONIN (MESH:D020230), Inflammation (MESH:D007249), neurodegeneration (MESH:D019636), neurotoxic (MESH:D020258), mental disorder (MESH:D001523), abuse (MESH:D019966), depression (MESH:D003866), CYTOKINES (MESH:D000080424), SENSITIVITY (MESH:D003807), impaired physical health (OMIM:603663), ADVERSITY (MESH:D064420), STEROIDS (MESH:D016114), cardiovascular disease (MESH:D002318)
- **Chemicals:** testosterone (MESH:D013739), methylprednisolone (MESH:D008775), Hyaluronan (MESH:D006820), pentose (MESH:D010429), glutamate (MESH:D018698), PRE (MESH:D004656), progesterone (MESH:D011374), noradrenaline (MESH:D009638), 11-keto-testosterone (MESH:C003600), cortisone (MESH:D003348), pregnenolone (MESH:D011284), corticosterone (MESH:D003345), DHEAS (MESH:D019314), androstenedione (MESH:D000735), CORTISOL (MESH:D006854), DHEA (MESH:D003687), steroids (MESH:D013256), 5-androstenediol (MESH:D015114), Serotonin (MESH:D012701), dopamine (MESH:D004298), benzodiazepines (MESH:D001569), 7alpha-OH-DHEA (-), amines (MESH:D000588), NADPH (MESH:D009249), dexamethasone (MESH:D003907)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606], Rodentia (rodent, order) [taxon 9989], Rattus norvegicus (brown rat, species) [taxon 10116]
- **Mutations:** Val66Met, Val(158)Met

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12933023/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12933023/full.md

## References

328 references — full list in the complete paper: https://tomesphere.com/paper/PMC12933023/full.md

---
Source: https://tomesphere.com/paper/PMC12933023